Exosomal MicroRNAs as Novel Cell-Free Therapeutics in Tissue Engineering and Regenerative Medicine

Zeng, Eric Z.; Chen, Isabelle; Chen, Xingchi; Yuan, Xuegang

doi:10.3390/biomedicines10102485

Cited by 10 publications

(13 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On top of directly utilizing EVs derived from MSCs, there also exist attempts to manipulate the EVs ex vivo in order to facilitate a more optimal therapeutic approach. One of the most used methods for manipulation of EVs includes the modulation of their miRNA content (Yoo et al, 2018;Abreu et al, 2021;Zeng et al, 2022). This is performed by a procedure termed exo-miRNA loading, which is done in one of two ways: 1) producing a cell line over-expressing the desired miRNA or 2) loading EVs with miRNA using chemical or physical methods (Munir et al, 2020).…”

Section: Application Of Extracellular Vesicles Derived From Mscsmentioning

confidence: 99%

“…In addition to direct transplantation of MSCs, there also exist studies researching the application of MSCs' byproducts, such as exosomes (Zeng et al, 2022). For example, a 2021. study by Chen et al has shown that WJ-MSC-derived exosomes loaded with miR-29a, which mainly affects histone deacetylase 4 (HDAC4) (Müller et al, 2016), caused a significant decrease in nuclear HDAC4 (Chen et al, 2021b).…”

Section: Alzheimers' Diseasementioning

confidence: 99%

“…On top of miR-29, studies have also shown beneficial effects of miR-21, miR-22, miR-1246, wherein these miRNAs slowed cognitive deterioration in AD mice through regulation of neuroinflammation and synaptic damage (Cui et al, 2018;Cone et al, 2021). With that, in order to optimize miR cargo delivery and, therewith, develop novel AD treatments, one must first understand the intricate connection between progression of AD and exo-miRs (Zeng et al, 2022).…”

Section: Alzheimers' Diseasementioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Isakovic

Šerer

Barišić

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Neurological disorders are recognized as major causes of death and disability worldwide. Because of this, they represent one of the largest public health challenges. With awareness of the massive burden associated with these disorders, came the recognition that treatment options were disproportionately scarce and, oftentimes, ineffective. To address these problems, modern research is increasingly looking into novel, more effective methods to treat neurological patients; one of which is cell-based therapies. In this review, we present a critical analysis of the features, challenges, and prospects of one of the stem cell types that can be employed to treat numerous neurological disorders—mesenchymal stem cells (MSCs). Despite the fact that several studies have already established the safety of MSC-based treatment approaches, there are still some reservations within the field regarding their immunocompatibility, heterogeneity, stemness stability, and a range of adverse effects—one of which is their tumor-promoting ability. We additionally examine MSCs’ mechanisms of action with respect to in vitro and in vivo research as well as detail the findings of past and ongoing clinical trials for Parkinson’s and Alzheimer’s disease, ischemic stroke, glioblastoma multiforme, and multiple sclerosis. Finally, this review discusses prospects for MSC-based therapeutics in the form of biomaterials, as well as the use of electromagnetic fields to enhance MSCs’ proliferation and differentiation into neuronal cells.

show abstract

Section: Application Of Extracellular Vesicles Derived From Mscsmentioning

confidence: 99%

Section: Alzheimers' Diseasementioning

confidence: 99%

Section: Alzheimers' Diseasementioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Isakovic

Šerer

Barišić

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Circulating free miRNAs and exomiRs have been proposed as promising non-invasive biomarkers for cancer diagnosis, prognosis, treatment and monitoring of disease progression [ 170 ]. Currently, the potential of exomiRs is being assessed as a novel therapy strategy of cancer and other diseases [ 171 , 172 , 173 ]. In BC, c-miRNAs and exomiRs have been shown to affect essential features such as tumor growth, invasion and angiogenesis [ 174 ].…”

Section: Non-coding Rnasmentioning

confidence: 99%

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck¹,

Ortmann²

2023

Cancers

View full text Add to dashboard Cite

The largest part of human DNA is transcribed into RNA that does not code for proteins. These non-coding RNAs (ncRNAs) are key regulators of protein-coding gene expression and have been shown to play important roles in health, disease and therapy response. Today, endocrine therapy of ERα-positive breast cancer (BC) is a successful treatment approach, but resistance to this therapy is a major clinical problem. Therefore, a deeper understanding of resistance mechanisms is important to overcome this resistance. An increasing amount of evidence demonstrate that ncRNAs affect the response to endocrine therapy. Thus, ncRNAs are considered versatile biomarkers to predict or monitor therapy response. In this review article, we intend to give a summary and update on the effects of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) on estrogen signaling in BC cells, this pathway being the target of endocrine therapy, and their role in therapy resistance. For this purpose, we reviewed articles on these topics listed in the PubMed database. Finally, we provide an assessment regarding the clinical use of these ncRNA types, particularly their circulating forms, as predictive BC biomarkers and their potential role as therapy targets to overcome endocrine resistance.

show abstract

“…They are emerging as key regulators of intercellular communication in health and disease with potential relevance as biomarkers and therapeutic strategies in different pathological conditions [54,55]. EVs can transfer their bioactive cargo from donor to recipient cells and influence the biological function of the target cell.…”

Section: Introductionmentioning

confidence: 99%

Correlation Between Endoglin and Malignant Phenotype in Human Melanoma Cells: Analysis of hsa-mir-214 and hsa-mir-370 in Cells and Their Extracellular Vesicles

Ruíz-Llorente

Ruiz-Rodríguez

Savini

et al. 2023

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Endoglin (CD105) is an auxiliary receptor of transforming growth factor (TGF)-β family members that is expressed in human melanomas. It is heterogeneously expressed by primary and metastatic melanoma cells, and endoglin targeting as a therapeutic strategy for melanoma tumors is currently been explored. However, its involvement in tumor development and malignancy is not fully understood. Here, we find that endoglin expression correlates with malignancy of primary melanomas and cultured melanoma cell lines. Next, we have analyzed the effect of ectopic endoglin expression on two miRNAs (hsa-mir-214 and hsa-mir-370), both involved in melanoma tumor progression and endoglin regulation. We show that compared with control cells, overexpression of endoglin in the WM-164 melanoma cell line induces; (i) a significant increase of hsa-mir-214 levels in small extracellular vesicles (EVs) as well as an increased trend in cells; and (ii) significantly lower levels of hsa-mir-370 in the EVs fractions, whereas no significant differences were found in cells. As hsa-mir-214 and hsa-mir-370 are not just involved in melanoma tumor progression, but they can also target endoglin-expressing endothelial cells in the tumor vasculature, these results suggest a complex and differential regulatory mechanism involving the intracellular and extracellular signaling of hsa-mir-214 and hsa-mir-370 in melanoma development and progression.

show abstract

Exosomal MicroRNAs as Novel Cell-Free Therapeutics in Tissue Engineering and Regenerative Medicine

Cited by 10 publications

References 175 publications

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Correlation Between Endoglin and Malignant Phenotype in Human Melanoma Cells: Analysis of hsa-mir-214 and hsa-mir-370 in Cells and Their Extracellular Vesicles

Contact Info

Product

Resources

About